An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505185-28-00

Acronym

CO43805

Enrollment

Registered

2024-07-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Hodgkin Lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026